Nanobiotix S.A. (NBTX)
| Market Cap | 1.57B +79.2% |
| Revenue (ttm) | 13.15M +13.3% |
| Net Income | -60.40M |
| EPS | -1.22 |
| Shares Out | 50.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,295 |
| Open | 30.49 |
| Previous Close | 29.70 |
| Day's Range | 29.25 - 30.75 |
| 52-Week Range | 18.58 - 57.14 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 54.24 (+80.92%) |
| Earnings Date | Sep 24, 2026 |
About NBTX
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th... [Read more]
Analyst Summary
According to 5 analysts, the average rating for NBTX stock is "Strong Buy." The 12-month stock price target is $54.24, which is an increase of 80.92% from the latest price.
News
Nanobiotix announces updated results from Phase 1 Study 1100 of JNJ-1900
Nanobiotix (NBTX) announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100. The study evaluates JNJ-1900, which wo...
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acce...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix Names Arnd Christ CFO As Rhijn Steps Down
(RTTNews) - Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company developing physics-based nano-therapeutics for cancer and other major diseases, announced the appointment of Arnd Christ...
Nanobiotix appoints Arnd Christ CFO
Nanobiotix (NBTX) announced the appointment of Arnd Christ as CFO and member of the company’s executive board, effective October 1. Christ brings more than two decades of financial leadership in…
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approache...
Nanobiotix S.A. (NBTX) Earnings Review: Clinical Progress Meets a Cash-Runway Test
What the latest reported quarter says about the current operating story and the main business drivers Nanobiotix S.A. (NBTX) is... The post Nanobiotix S.A. (NBTX) Earnings Review: Clinical Progress Me...
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approa...
Nanobiotix Earnings release: H1 2026
Nanobiotix released its H1 2026 earnings on September 24, 2026, summarizing the period's financial results.
Nanobiotix Quarterly report: H1 2026
Nanobiotix has published its H1 2026 quarterly earnings report on September 24, 2026.
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix assumed with a Buy at Guggenheim
Guggenheim assumed coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target. The firm’s investment thesis is centered on the company’s first-in-class radio-enhancer, JNJ-1900, which is par...
Nanobiotix announces updated safety, efficacy data from JNJ-1900 study
Nanobiotix (NBTX) announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center…
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deem...
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approach...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Voting Rights and Shares Capital of the Company
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité d...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029
(RTTNews) - Nanobiotix S.A. (NBTX), a clinical-stage biotechnology firm, reported a financial and operational update for its first quarter of 2026.
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Nanobiotix Earnings release: Q1 2026
Nanobiotix released its Q1 2026 earnings on June 2, 2026, summarizing the period's financial results.
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix Exercises Underwriters' Option In Global Offering, Gross Proceeds Reach $100 Mln
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical stage company, on Friday announced that underwriters of its global offering had fully exercised the option to purchase additional American Depositar...
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...